Exelixis | EXEL - Operating Profit


Exelixis reported $248.41M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bayer EUR 827M 2.7B Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 248.41M 2.93M Jun/2026
Genmab DKK 407M 182M Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sanofi EUR 2.27B 771M Mar/2026
Takeda JPY 201.42B 215.04B Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026